Merck’s Revised Biosimilar Strategy Poised To Deliver
This article was originally published in The Pink Sheet Daily
Executive Summary
The big pharma has five biosimilars in Phase III development with its partner Samsung Bioepis, and expects to file them for regulatory approval in 2015 and 2016.